Physician profile
Barbara Decker
NPI 1275951022
$43,851.77
in general payments reported to CMS, 2019-2025
24 companies · $5,614 in 2025
The $5,614 reported for 2025 was more than what 88% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31K · 2023: $989 · 2024: $5,776 · 2025: $5,614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,594 · Food and Beverage: $3,617 · Travel and Lodging: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,594.00 |
| Food and Beverage | $3,616.52 |
| Travel and Lodging | $169.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ceribell, INC. | $31,471.88 | 2019 | |
| Neurelis, INC. | $9,163.89 | 2023-2025 | Valtoco |
| Sk Life Science, INC. | $824.79 | 2023-2025 | Xcopri |
| Abbvie INC. | $421.89 | 2023-2025 | Ubrelvy, Qulipta |
| Argenx US, INC. | $300.92 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
| Ucb, INC. | $292.91 | 2023-2025 | Nayzilam, Rystiggo |
| Jazz Pharmaceuticals INC. | $203.37 | 2023-2025 | |
| Tg Therapeutics, INC. | $169.98 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $149.87 | 2023-2025 | Ajovy, Austedo Xr |
| Eisai INC. | $138.94 | 2024-2025 | |
| Pfizer INC. | $100.73 | 2024-2025 | |
| Lundbeck LLC | $85.49 | 2023-2025 | Vyepti |
| Novartis Pharmaceuticals Corporation | $79.50 | 2024-2025 | |
| Biogen, INC. | $70.08 | 2024-2025 | Spinraza, Tysabri |
| Acadia Pharmaceuticals INC | $56.59 | 2025 | Daybue |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $49.78 | 2024 | Amyvid, Kisunla |
| Tanabe Pharma America, INC. | $48.84 | 2023-2024 | |
| Amgen INC. | $47.77 | 2024-2025 | Uplizna |
| Alexion Pharmaceuticals, INC. | $44.50 | 2023-2024 | Ultomiris |
| Microtransponder, INC. | $37.21 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $29.16 | 2023 | Rexulti |
| Grifols USA, LLC | $26.37 | 2024 | Gamunex-C |
| Azurity Pharmaceuticals, INC. | $22.33 | 2023 | Eprontia |
| Livanova USA, INC. | $14.98 | 2025 | Vns Therapy Sentiva Model 1000 Generator |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Decker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.